Eikon Therapeutics Inks Licensing Deals and Raises Funds for Drug Pipeline Expansion
US biotech company Eikon Therapeutics has announced three in-licensing deals this week, one of which...
Company
Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics
The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177),...
Ucello Therapeutics Secures RMB 150 Million in Series A+ Financing for CAR-T Cell Therapy
Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in...
Eversana Forms Strategic Alliance with China Resource Pharmaceutical for Healthcare Expansion
US-based commercial services provider Eversana has announced a strategic alliance with China Resource Pharmaceutical Commercial...
Adcendo ApS Expands Partnership with Duality Biologics for Two Additional ADCs
Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody...
Jiangsu Hengrui Medicine’s SHR-1905 and SHR7280 Receive NMPA Clinical Trial Approvals
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals from...
Brii Biosciences Initiates Phase I Study for BRII-297 in Australia
China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I...
AIM Vaccine’s Omicron BA.5 mRNA Vaccine Shows 73.16% Efficacy in China Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron...
Coherus and Junshi Biosciences Await FDA Decision on Toripalimab After Inspection
US-based Coherus Biosciences Inc., (NASDAQ: CHRS) has disclosed that the US FDA has recently completed...
Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced receiving market approval from the National...
Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R/R MM
China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia’s Pharmaceutical Benefits Scheme (PBS)...
Amoytop Biotech and Fosun Pharmaceutical Ink Licensing Deal for Pegfilgrastim in China
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced a licensing agreement with Shanghai Fosun...
HighField Biopharmaceuticals Presents Promising HF1K16 Data at ASCO Annual Meeting
Hangzhou-based biotech HighField Biopharmaceuticals has revealed the publication of an abstract at this year’s American...
Luzhu Biotechnology’s Herpes Zoster Vaccine LZ901 Concludes Phase II Study
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading maker of human vaccines and therapeutic...
CMS Receives NMPA Approval for Tildrakizumab for Plaque Psoriasis Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced receiving marketing approval from the National...
Cutia Therapeutics Lists on HKEX with HKD527 Million IPO for Dermatology Therapies
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has successfully made its initial public offering (IPO),...
CSPC Pharmaceutical’s AlaMab Therapeutics Presents Positive ALMB-0168 Data at ASCO
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, AlaMab Therapeutics Inc.,...
Betta Pharmaceuticals Secures Exclusive Rights to C4 Therapeutics’ CFT8919 in Greater China
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced an exclusive licensing agreement with US...
Lynk Pharmaceuticals Secures RMB 200 Million in Series C1 Financing Round
China-based Lynk Pharmaceuticals Co., Ltd has successfully raised RMB 200 million (USD 28.3 million) through...
BeiGene’s Brukinsa Receives Canadian Approval for Chronic Lymphocytic Leukemia
China-based BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that its Bruton’s tyrosine...